Buprenorphine
What buprenorphine is used for
Buprenorphine is a partial opioid agonist. This English record is specifically based on the buprenorphine-only sublingual tablet used to treat opioid dependence, also called opioid use disorder. Treatment includes clinical follow-up, counselling and psychosocial support. Other buprenorphine products have different approved uses, routes and precautions; a skin patch, injection, or combination with naloxone should not be treated as the same product.
The information here explains uses, safety and documented interaction mechanisms. It does not provide an induction schedule, an opioid-conversion calculation or a reason to change a prescribed treatment. Starting buprenorphine while another opioid is still active can trigger withdrawal, so switching requires a clinician familiar with the specific products.
Breathing and sedation risks
Buprenorphine can cause dangerous respiratory depression, particularly with alcohol, benzodiazepines or other medicines that depress the central nervous system. Its partial-agonist action does not make an overdose impossible. Tell the treatment team about prescribed sleeping medicines, anxiety treatment, muscle relaxants and other opioids.
For a person receiving treatment for opioid use disorder, a benzodiazepine prescription is a reason for coordinated risk management, not a reason to abandon care without medical advice. The label recommends careful assessment and a plan to reduce the risks of combining depressants.
Important drug interactions
Medicines that inhibit or induce CYP3A4 can change buprenorphine exposure. A change may become apparent when another medicine is started or stopped, even after a previously stable period. The effect of an HIV treatment is regimen-specific: not every protease inhibitor produces the same clinical effect, and the label describes pharmacokinetic changes with some antiretrovirals without a corresponding clinical effect in the study.
Serotonergic medicines can add a risk of serotonin syndrome. Anticholinergic medicines may worsen constipation or urinary retention, while opioids can reduce the response to diuretics. The interaction links accompanying this record apply these warnings to identified active ingredients rather than assuming every medicine in a broad treatment category behaves alike.
Side effects and ongoing checks
Headache, nausea, constipation, sweating, vomiting and insomnia were reported in clinical trials. Liver problems, adrenal insufficiency, severe allergy and problems with breathing are more serious concerns that need assessment. Transmucosal buprenorphine products have also been associated with serious dental problems, including tooth decay and tooth loss. Maintain dental follow-up and follow the oral-care advice supplied with the prescribed product.
Pregnancy, breastfeeding and urgent symptoms
Pregnancy and breastfeeding need a specialist benefit-risk discussion. Untreated opioid dependence carries risks as well, and a treatment should not be stopped abruptly on the basis of a web summary. A newborn may develop opioid withdrawal after prolonged exposure during pregnancy; breastfed infants should be watched for unexpected sleepiness and breathing difficulty.
Seek emergency help for very slow breathing, inability to wake, collapse or a suspected overdose. Ask the prescriber about an opioid-overdose reversal medicine and a response plan. Keep all opioid medicines out of reach of children and use the product-specific storage and disposal instructions.
Sources and source check
The prescribing information linked below was checked on 4 November 2026. This is a source-based educational summary, not a claim of an independent specialist review. Local authorisations, available formulations and clinical recommendations may differ.